';

Tuberculosis

Taking the fight against drug resistance into the community

Utilising ultra-sensitive molecular diagnostics QuantuMDx will be bringing gold-standard diagnostics into the community.

QPOC_QP00

The Problem

Healthcare systems face many barriers, including a lack of finance, testing expertise and infrastructure, to the provision of TB diagnostics.

5% of patients with newly diagnosed tuberculosis underwent drug sensitivity testing in 2012
9% of patients with cases being ‘retreated’ underwent Drug Sensitivity Testing in 2012
Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.

Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available in 2018.

However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.

Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.

Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available in 2018.

However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.

9m people infected in 2013
480,000 people infected with MDR-TB in 2013
There were 1.5m TB related deaths in 2013

TB treatment $2,000 per patient - rises more than hundredfold to up to $250,000 per patient with anti-microbial resistant TB.

3 million cases ‘missed’ by healthcare systems
MDR-TB: multi drug resistant tuberculosis - does not respond to initial treatment
Less than 1 in 4 MDR-TB cases diagnosed
3 million cases ‘missed’ by healthcare systems
MDR-TB: multi drug resistant tuberculosis - does not respond to initial treatment
Less than 1 in 4 MDR-TB cases diagnosed
The Solution

QuantuMDx is utilising its superior multiplexing capability to develop a drug susceptibility test for the future drug regimens. We have partnered with FIND to overcome the many challenges of sample preparation.

“It seems almost incredible that during this century and the previous one, a single disease, tuberculosis, was responsible for the deaths of approximately a thousand million human beings.”
FIND
Nonprofit Organization Management

Subscribe to our e-newsletter and keep up to date with QuantuMDx

THE FUTURE OF DIAGNOSTICS

Partnerships

Clinical development and trial partners, access to samples.

Global Partnerships, Global Vision
  • DNA-XT™
    Sample Preparation

    Our next generation spin column will purify high-quality DNA for PCR, sequencing and other molecular processes.

  • Diagnostics
    Under the Tree

    Supporting disease eradication efforts with simple and accurate diagnostic testing in the community.

  • Q-POC™
    Portable Diagnostics

    Our portable, battery-operated molecular diagnostic device will provide sample-to-result testing in less than 20 minutes.

  • Internet of Life™
    Networking Disease Data

    Globally distributed Q-POC devices will geotag and anonymise pathogen data, and send it to the cloud for real-time disease and drug resistance monitoring.

Contact

Contact

Contact